{"product_id":"humanwell-pestle-analysis","title":"Humanwell Healthcare PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Smarter Strategic Decisions with a Complete PESTEL View\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how political shifts, healthcare spending trends, and rapid biotech innovation are shaping Humanwell Healthcare’s strategic outlook—our concise PESTLE snapshot highlights key external drivers and risks you need to know. Unlock the full PESTLE Analysis for actionable, investor-grade insights, editable charts, and a detailed risk-opportunity matrix to support deals, strategy, or investment theses—download the complete report now.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNational Volume-Based Procurement expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBy late 2025 China expanded Volume-Based Procurement to high-value injectables and anesthetics, pressuring Humanwell to accept double-digit price cuts—average tender-driven cuts reached ~55% in pilot drugs—reducing legacy margins while boosting volumes via state channels that accounted for ~38% of company sales in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical trade and supply chain stability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOngoing trade tensions between the US, EU and China have prompted tighter export controls on APIs, raising compliance costs for Humanwell by an estimated 5–8% of COGS in 2024; the firm must clear complex regulatory hurdles as it expands manufacturing in North America and Africa.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment incentives for pharmaceutical innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eState-led initiatives in China provide subsidies and fast-track approvals—RMB 10+ billion in innovation funds and priority review reducing approval times by ~30%—targeting core technologies and unmet needs; Humanwell’s R\u0026amp;D in CNS and reproductive medicine aligns with these priorities. The company received government grants covering up to 20% of eligible R\u0026amp;D costs in 2024, boosting its pipeline and positioning it to scale globally against multinationals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory alignment with international standards\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe NMPA aligned drug review processes more closely with ICH by end-2025, cutting average review timelines by ~15% and improving global acceptability of Chinese dossiers.\u003c\/p\u003e\n\u003cp\u003eThis eases Humanwell’s pathway into Western markets but raises domestic QA and clinical-data requirements, increasing R\u0026amp;D compliance costs—estimated +5–8% of trial budgets.\u003c\/p\u003e\n\u003cp\u003eMaintaining ICH conformity is essential to sustain Humanwell’s global launches and keep clinical trial success rates above the industry average of ~12–15%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eICH alignment completed end-2025; review times down ~15%\u003c\/li\u003e\n\u003cli\u003eHigher QA\/clinical-data standards raise trial costs ~5–8%\u003c\/li\u003e\n\u003cli\u003eSupports Western market entry and sustains ~12–15% trial success benchmark\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare infrastructure investment in emerging markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePolitical support for the Belt and Road Initiative has enabled Humanwell to enter Southeast Asia and Africa, where government agreements helped secure $120m in contracts in 2024 to supply essential medicines.\u003c\/p\u003e\n\u003cp\u003eThe company is using government-to-government partnerships to build distribution networks and two manufacturing hubs planned for 2025–2026, targeting markets with CAGR drug demand \u0026gt;8%.\u003c\/p\u003e\n\u003cp\u003eThese political alliances create a stable framework for long-term investment in regions where per-capita pharmaceutical spending is rising 6–10% annually.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 contracts: $120m\u003c\/li\u003e\n\u003cli\u003eTarget markets CAGR: \u0026gt;8%\u003c\/li\u003e\n\u003cli\u003ePer-capita pharma spending growth: 6–10% annually\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolicy shocks: Deep VBP cuts, state channels \u0026amp; BRI lift volumes; costs and exports pressured\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical shifts—expanded VBP causing ~55% tender price cuts, state channels = ~38% of 2024 sales, and $120m BRI contracts—compressed margins but boosted volumes and market access; NMPA ICH alignment cut review times ~15% yet raised QA\/trial costs ~5–8%, while export controls added ~5–8% to COGS for overseas expansion.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVBP tender cuts\u003c\/td\u003e\n\u003ctd\u003e~55%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eState-channel sales 2024\u003c\/td\u003e\n\u003ctd\u003e~38%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBRI contracts 2024\u003c\/td\u003e\n\u003ctd\u003e$120m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNMPA review time reduction\u003c\/td\u003e\n\u003ctd\u003e~15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\/QA cost increase\u003c\/td\u003e\n\u003ctd\u003e~5–8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExport-control impact on COGS\u003c\/td\u003e\n\u003ctd\u003e~5–8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how macro-environmental factors uniquely affect Humanwell Healthcare across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with data-backed, region-specific insights to identify risks and opportunities for executives, investors, and strategists.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, visually segmented PESTLE snapshot for Humanwell Healthcare that clarifies regulatory, economic, and technological risks—ready to drop into presentations or share across teams for fast alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRising healthcare expenditure and insurance coverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBy end-2025 China’s public and private healthcare spending surpassed RMB 10 trillion, fueled by universal coverage expansion and a middle-class surge, creating a larger addressable market for Humanwell’s specialty therapies.\u003c\/p\u003e\n\u003cp\u003eEconomic growth and higher per-capita medical expenditure boosted demand for high-end anesthesiology and pain-management products where Humanwell holds key offerings.\u003c\/p\u003e\n\u003cp\u003eHigher reimbursement rates for innovative drugs—average drug reimbursement increases of 8–12% in 2024–25—improve payback on R\u0026amp;D, allowing Humanwell to capture greater value from new launches.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImpact of global inflation on production costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePersistent inflation raised raw material, energy and skilled labor costs for pharmaceutical manufacturing—input inflation averaged about 8–10% in China in 2023–24, lifting API and packaging prices by roughly 12% year-on-year and raising Humanwell’s COGS pressure.\u003c\/p\u003e\n\u003cp\u003eHumanwell is deploying advanced cost-control and supply-chain optimizations—inventory turnover improved to 5.2x in 2024 and procurement savings initiatives cut unit input costs by an estimated 4–6%.\u003c\/p\u003e\n\u003cp\u003eGovernment price caps limit Humanwell’s ability to fully pass higher costs to patients; with regulated margins on essential drugs, internal efficiency remains the primary buffer to protect operating margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency exchange rate volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAs a company with significant international operations, Humanwell faces Yuan volatility versus the US Dollar and Euro—CNY moved ~5.8% vs. USD in 2024—affecting translated earnings from overseas subsidiaries and raising costs for imported specialized equipment and chemical precursors; in 2024 FX translation swung reported revenue by an estimated RMB 220–300 million. The firm uses forwards, options and cross-currency swaps to hedge exposure and stabilize cash flows.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital market access and R\u0026amp;D financing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCapital markets have tightened: in 2024 biotech IPOs fell 45% year-over-year and venture funding dropped 30%, shifting investor preference to revenue-generating and late-stage assets.\u003c\/p\u003e\n\u003cp\u003eHumanwell’s 2025 revenue of RMB 8.3 billion and diversified product portfolio enable access to debt at ~6–7% vs. 10–12% for smaller peers, lowering capital costs.\u003c\/p\u003e\n\u003cp\u003eThat funding stability sustained R\u0026amp;D spend near 12% of sales (~RMB 1.0 billion in 2025), preserving pipeline progress despite market volatility.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 biotech IPOs −45% YoY, VC funding −30% YoY\u003c\/li\u003e\n\u003cli\u003eHumanwell 2025 revenue RMB 8.3B; R\u0026amp;D ≈12% of sales (~RMB 1.0B)\u003c\/li\u003e\n\u003cli\u003eBorrowing costs ~6–7% vs. 10–12% for pre-revenue peers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEconomic shifts in specialized therapeutic segments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDemand for CNS drugs and reproductive health products shows high elasticity as consumers spend more on mental health and family planning; global CNS market reached about USD 120bn in 2024 with reproductive health ~USD 35bn, supporting premium and value segments.\u003c\/p\u003e\n\u003cp\u003eHumanwell leverages this by offering high-end clinical treatments and lower-cost consumer products, driving revenue diversification—group R\u0026amp;D and product launches grew 18% YoY in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh elasticity: CNS ~USD120bn (2024)\u003c\/li\u003e\n\u003cli\u003eReproductive health ~USD35bn (2024)\u003c\/li\u003e\n\u003cli\u003eHumanwell product\/R\u0026amp;D growth +18% YoY (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHumanwell rides China’s \u0026gt;RMB10tr healthcare boom: RMB8.3b sales, R\u0026amp;D 12% amid inflation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRobust healthcare spending (China \u0026gt;RMB10tr by end-2025) and rising per-capita medical expenditure fueled demand for Humanwell’s specialty anesthesiology, CNS and reproductive products; 2025 revenue RMB8.3b, R\u0026amp;D ~RMB1.0b (12%). Input inflation (2023–24 ~8–10%) pressured COGS while govt price caps limited pass-through; borrowing costs ~6–7% aided financing despite tighter biotech markets (2024 IPOs −45%, VC −30%).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eChina healthcare spend\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;RMB10tr (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHumanwell revenue\u003c\/td\u003e\n\u003ctd\u003eRMB8.3b (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e~RMB1.0b (12% sales)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInput inflation\u003c\/td\u003e\n\u003ctd\u003e8–10% (2023–24)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiotech markets\u003c\/td\u003e\n\u003ctd\u003eIPOs −45%, VC −30% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eHumanwell Healthcare PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Humanwell Healthcare PESTLE document you’ll receive after purchase—fully formatted, professionally structured, and ready to use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751901278585,"sku":"humanwell-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/humanwell-pestle-analysis.png?v=1772235904","url":"https:\/\/growthsharematrix.com\/products\/humanwell-pestle-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}